Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjay Rastogi

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
BMC Nephrology|February 9, 2022
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZESteven Fishbane, Martin Ford, Masafumi Fukagawa, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 13, 2019
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidismDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Journal of the American Society of Nephrology : JASN|June 16, 2019
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis HyperkalemiaSteven Fishbane, Martin Ford, Masafumi Fukagawa, et al.
Kidney Medicine|August 1, 2020
Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose TolvaptanRamy M Hanna, Juan Carlos Velez, Anjay Rastogi, et al.
Transplantation|July 16, 2008
Renal function impacts outcomes after intestinal transplantationMelissa J Watson, Robert S Venick, Fady Kaldas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2013
Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) TrialsDaniel B Ornt, Brett Larive, Anjay Rastogi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 19, 2015
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsJürgen Floege, Adrian C Covic, Markus Ketteler, et al.
Expert Review of Clinical Pharmacology|July 6, 2021
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agentAnjay Rastogi, Ramy M Hanna, Anita Mkrttchyan, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES StudySteven Fishbane, Carol A Pollock, Mohamed El-Shahawy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 20, 2020
The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)O Alison Potok, Joachim H Ix, Michael G Shlipak, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
BMC Nephrology|February 9, 2022
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZESteven Fishbane, Martin Ford, Masafumi Fukagawa, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 13, 2019
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidismDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Journal of the American Society of Nephrology : JASN|June 16, 2019
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis HyperkalemiaSteven Fishbane, Martin Ford, Masafumi Fukagawa, et al.
Kidney Medicine|August 1, 2020
Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose TolvaptanRamy M Hanna, Juan Carlos Velez, Anjay Rastogi, et al.
Transplantation|July 16, 2008
Renal function impacts outcomes after intestinal transplantationMelissa J Watson, Robert S Venick, Fady Kaldas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2013
Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) TrialsDaniel B Ornt, Brett Larive, Anjay Rastogi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 19, 2015
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsJürgen Floege, Adrian C Covic, Markus Ketteler, et al.
Expert Review of Clinical Pharmacology|July 6, 2021
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agentAnjay Rastogi, Ramy M Hanna, Anita Mkrttchyan, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES StudySteven Fishbane, Carol A Pollock, Mohamed El-Shahawy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 20, 2020
The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)O Alison Potok, Joachim H Ix, Michael G Shlipak, et al.
Pageof 10